Replimune Shares Surge 30% Following FDA Leadership Change
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 3 days ago
0mins
Should l Buy REPL?
Source: seekingalpha
Replimune Group Inc. shares surged approximately 30% on Wednesday, following the resignation of FDA Commissioner Marty Makary, indicating market optimism regarding new leadership and the company's future prospects.
Makary's resignation came amid reported pressure from President Trump, reflecting turmoil within the FDA and dissatisfaction with his leadership, potentially creating favorable conditions for Replimune's RP1 therapy resubmission. Despite Replimune's efforts to engage with the FDA through a Type A meeting prior to its RP1 therapy application, the FDA's rejection in April led to a significant drop in the company's stock, highlighting the substantial impact of FDA decisions on biopharma companies.
Investment group Galzus Research maintains a cautious buy rating on Replimune, suggesting that with Makary's departure, there is potential for RP1 resubmission, which could open new growth opportunities for the company.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy REPL?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on REPL
Wall Street analysts forecast REPL stock price to rise
7 Analyst Rating
4 Buy
3 Hold
0 Sell
Moderate Buy
Current: 4.930
Low
3.00
Averages
11.43
High
18.00
Current: 4.930
Low
3.00
Averages
11.43
High
18.00
About REPL
Replimune Group, Inc. is a clinical-stage biotechnology company engaged in the development of novel oncolytic immunotherapies. Its proprietary RPx platform is based on a potent HSV-1 backbone intended to maximize immunogenic cell death and the induction of a systemic anti-tumor immune response. The RPx platform is designed to have a unique dual local and systemic activity consisting of direct selective virus-mediated killing of the tumor resulting in the release of tumor-derived antigens and altering of the tumor microenvironment to ignite a systemic response. Its lead product candidate, RP1, is a selectively replicating version of HSV-1 that expresses GALV-GP R(-) and human GM-CSF. Its lead indication for its lead product candidate, RP1, is the potential treatment of advanced melanoma. Its pipeline product candidates include RP2 and RP3. It has designed its RP2 product candidate to express an anti-CTLA-4 antibody-like protein intended to block the inhibition of the immune response.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Pomerantz LLP Investigates Replimune for Securities Fraud
- Securities Fraud Investigation: Pomerantz LLP is investigating claims on behalf of Replimune Group, Inc. investors, focusing on whether the company and its executives engaged in securities fraud or other unlawful business practices, highlighting serious concerns regarding corporate governance.
- FDA Response Letter: On April 10, 2026, Replimune announced it received a Complete Response Letter (CRL) from the FDA, indicating that there was disagreement over the sufficiency of the data set supporting its Biologics License Application (BLA), which may impact future product approval plans.
- Stock Price Plunge: Following the FDA news, Replimune's stock price fell by $3.06, or 64.29%, closing at $1.70 per share on April 13, 2026, reflecting market pessimism regarding the company's future prospects.
- Legal Firm Background: Pomerantz LLP, recognized as a leading firm in securities class action litigation, has recovered numerous multimillion-dollar damages for victims of securities fraud, demonstrating its strong influence and expertise in handling such cases.
See More
FDA Commissioner's Departure Triggers Biotech Market Reactions
- Leadership Change: The departure of FDA Commissioner Marty Makary is perceived as a positive signal for the biotech sector, although analysts warn that the industry may face pressure until a permanent replacement is found, potentially leading to market volatility.
- Market Reaction: The Nasdaq biotechnology index rose 1% on Tuesday, reflecting an initial positive response from investors to Makary's exit, particularly following his public disagreements with drugmakers like Replimune and Moderna.
- Increased Uncertainty: Analysts caution that the ongoing leadership vacuum at the FDA could result in more delays and unpredictability, diminishing the agency's ability to provide guidance and credible policy commitments, thereby impacting the investability of the biopharma ecosystem.
- Stock Performance: Shares of uniQure and Replimune rose by 5% and nearly 10%, respectively, indicating market optimism regarding new leadership, although Makary's departure also introduces uncertainty within the industry.
See More
Replimune Shares Surge 30% Following FDA Leadership Change
- Significant Stock Surge: Replimune (REPL) shares rose approximately 30% on Wednesday, following the resignation of FDA Commissioner Marty Makary, indicating market optimism regarding new leadership and the company's future prospects.
- Context of Leadership Change: Makary's resignation came amid reported pressure from President Trump, reflecting turmoil within the FDA and dissatisfaction with his leadership, potentially creating favorable conditions for Replimune's RP1 therapy resubmission.
- Therapy Application Challenges: Despite Replimune's efforts to engage with the FDA through a Type A meeting prior to its RP1 therapy application, the FDA's rejection in April led to a significant drop in the company's stock, highlighting the substantial impact of FDA decisions on biopharma companies.
- Market Outlook: Investment group Galzus Research maintains a cautious buy rating on Replimune, suggesting that with Makary's departure, there is potential for RP1 resubmission, which could open new growth opportunities for the company.
See More
Pomerantz LLP Investigates Replimune for Securities Fraud
- Securities Fraud Investigation: Pomerantz LLP is investigating claims on behalf of Replimune Group, Inc. investors, focusing on whether the company and its executives engaged in securities fraud or other unlawful business practices, which could lead to significant investor losses.
- FDA Response Letter: On April 10, 2026, Replimune announced it received a complete response letter (CRL) from the FDA regarding its Biologics License Application (BLA), indicating a disagreement with the FDA over the sufficiency of the data set, impacting the company's drug approval prospects.
- Stock Price Plunge: Following this news, Replimune's stock price fell by $3.06, or 64.29%, closing at $1.70 per share on April 13, 2026, reflecting extreme market pessimism regarding the company's future.
- Potential Legal Consequences: Pomerantz LLP, recognized for its expertise in securities litigation, may provide legal support to affected investors, further exacerbating the legal and financial risks faced by Replimune.
See More
FDA Commissioner Resignation Triggers Stock Movements
- Commissioner Resignation: Marty Makary's resignation from the FDA, following clashes with the Trump administration, has led to Kyle Diamantas stepping in as acting commissioner, potentially shifting FDA policy and its relationship with the pharmaceutical industry.
- Positive Market Reaction: Following Makary's exit, shares of Replimune (REPL) and uniQure (QURE) surged by 7% and 5%, respectively, indicating market optimism regarding the new leadership and future regulatory approaches.
- Strong Industry Backlash: Replimune faced significant criticism after the FDA rejected its melanoma therapy RP1, and Makary's departure may alter the regulatory landscape, impacting the company's strategic direction moving forward.
- Investor Sentiment Shift: While REPL has fallen 49% over the past year, QURE has gained 120%, reflecting differing investor sentiments towards the future prospects of both companies, especially in light of potential FDA policy changes.
See More
FDA Commissioner Makary Resigns Amid Controversy
- Makary Resignation: FDA Commissioner Marty Makary resigned on December 18, 2025, concluding a controversial tenure marked by criticism over the government's COVID-19 response and drug approval processes, which drew backlash from various stakeholders.
- Acting Commissioner Appointment: President Trump announced that Kyle Diamantas will temporarily take over as acting commissioner, having previously served as the top food official at the FDA, and will need to navigate the complex drug approval landscape left by Makary.
- Internal Turmoil Intensifies: Under Makary's leadership, staff morale at the FDA plummeted due to layoffs and departures, notably that of cancer regulator Richard Pazdur, leading to increased distrust in leadership and impacting the agency's stability.
- Drug Approval Controversies: During Makary's tenure, the FDA rejected several rare disease treatments, raising concerns within the pharmaceutical industry, particularly as negotiations for the reauthorization of the Prescription Drug User Fee Act highlighted the industry's sensitivity to leadership changes at the FDA.
See More
Pomerantz LLP Investigates Replimune for Securities Fraud
- Securities Fraud Investigation: Pomerantz LLP is investigating claims on behalf of Replimune Group, Inc. investors, focusing on whether the company and its executives engaged in securities fraud or other unlawful business practices, highlighting serious concerns regarding corporate governance.
- FDA Response Letter: On April 10, 2026, Replimune announced it received a Complete Response Letter (CRL) from the FDA, indicating that there was disagreement over the sufficiency of the data set supporting its Biologics License Application (BLA), which may impact future product approval plans.
- Stock Price Plunge: Following the FDA news, Replimune's stock price fell by $3.06, or 64.29%, closing at $1.70 per share on April 13, 2026, reflecting market pessimism regarding the company's future prospects.
- Legal Firm Background: Pomerantz LLP, recognized as a leading firm in securities class action litigation, has recovered numerous multimillion-dollar damages for victims of securities fraud, demonstrating its strong influence and expertise in handling such cases.
See More
FDA Commissioner's Departure Triggers Biotech Market Reactions
- Leadership Change: The departure of FDA Commissioner Marty Makary is perceived as a positive signal for the biotech sector, although analysts warn that the industry may face pressure until a permanent replacement is found, potentially leading to market volatility.
- Market Reaction: The Nasdaq biotechnology index rose 1% on Tuesday, reflecting an initial positive response from investors to Makary's exit, particularly following his public disagreements with drugmakers like Replimune and Moderna.
- Increased Uncertainty: Analysts caution that the ongoing leadership vacuum at the FDA could result in more delays and unpredictability, diminishing the agency's ability to provide guidance and credible policy commitments, thereby impacting the investability of the biopharma ecosystem.
- Stock Performance: Shares of uniQure and Replimune rose by 5% and nearly 10%, respectively, indicating market optimism regarding new leadership, although Makary's departure also introduces uncertainty within the industry.
See More
Replimune Shares Surge 30% Following FDA Leadership Change
- Significant Stock Surge: Replimune (REPL) shares rose approximately 30% on Wednesday, following the resignation of FDA Commissioner Marty Makary, indicating market optimism regarding new leadership and the company's future prospects.
- Context of Leadership Change: Makary's resignation came amid reported pressure from President Trump, reflecting turmoil within the FDA and dissatisfaction with his leadership, potentially creating favorable conditions for Replimune's RP1 therapy resubmission.
- Therapy Application Challenges: Despite Replimune's efforts to engage with the FDA through a Type A meeting prior to its RP1 therapy application, the FDA's rejection in April led to a significant drop in the company's stock, highlighting the substantial impact of FDA decisions on biopharma companies.
- Market Outlook: Investment group Galzus Research maintains a cautious buy rating on Replimune, suggesting that with Makary's departure, there is potential for RP1 resubmission, which could open new growth opportunities for the company.
See More
Pomerantz LLP Investigates Replimune for Securities Fraud
- Securities Fraud Investigation: Pomerantz LLP is investigating claims on behalf of Replimune Group, Inc. investors, focusing on whether the company and its executives engaged in securities fraud or other unlawful business practices, which could lead to significant investor losses.
- FDA Response Letter: On April 10, 2026, Replimune announced it received a complete response letter (CRL) from the FDA regarding its Biologics License Application (BLA), indicating a disagreement with the FDA over the sufficiency of the data set, impacting the company's drug approval prospects.
- Stock Price Plunge: Following this news, Replimune's stock price fell by $3.06, or 64.29%, closing at $1.70 per share on April 13, 2026, reflecting extreme market pessimism regarding the company's future.
- Potential Legal Consequences: Pomerantz LLP, recognized for its expertise in securities litigation, may provide legal support to affected investors, further exacerbating the legal and financial risks faced by Replimune.
See More
FDA Commissioner Resignation Triggers Stock Movements
- Commissioner Resignation: Marty Makary's resignation from the FDA, following clashes with the Trump administration, has led to Kyle Diamantas stepping in as acting commissioner, potentially shifting FDA policy and its relationship with the pharmaceutical industry.
- Positive Market Reaction: Following Makary's exit, shares of Replimune (REPL) and uniQure (QURE) surged by 7% and 5%, respectively, indicating market optimism regarding the new leadership and future regulatory approaches.
- Strong Industry Backlash: Replimune faced significant criticism after the FDA rejected its melanoma therapy RP1, and Makary's departure may alter the regulatory landscape, impacting the company's strategic direction moving forward.
- Investor Sentiment Shift: While REPL has fallen 49% over the past year, QURE has gained 120%, reflecting differing investor sentiments towards the future prospects of both companies, especially in light of potential FDA policy changes.
See More
FDA Commissioner Makary Resigns Amid Controversy
- Makary Resignation: FDA Commissioner Marty Makary resigned on December 18, 2025, concluding a controversial tenure marked by criticism over the government's COVID-19 response and drug approval processes, which drew backlash from various stakeholders.
- Acting Commissioner Appointment: President Trump announced that Kyle Diamantas will temporarily take over as acting commissioner, having previously served as the top food official at the FDA, and will need to navigate the complex drug approval landscape left by Makary.
- Internal Turmoil Intensifies: Under Makary's leadership, staff morale at the FDA plummeted due to layoffs and departures, notably that of cancer regulator Richard Pazdur, leading to increased distrust in leadership and impacting the agency's stability.
- Drug Approval Controversies: During Makary's tenure, the FDA rejected several rare disease treatments, raising concerns within the pharmaceutical industry, particularly as negotiations for the reauthorization of the Prescription Drug User Fee Act highlighted the industry's sensitivity to leadership changes at the FDA.
See More
